Explore

Georgia State Researchers Advance Understanding of Tick-Borne Powassan Virus

Georgia State Researchers Advance Understanding of Tick-Borne Powassan Virus

Researchers at Georgia State University are making significant strides in understanding the tick-borne Powassan virus, a rare but increasingly reported infection in the U.S. that can cause severe brain inflammation. With cases on the rise, particularly in the Northeast and Great Lakes regions, scientists know relatively little about how the virus causes serious illness. Dr. Mukesh Kumar, an associate professor and director of the Molecular Basis of Disease program, leads a team that has published three recent studies. These studies focus on developing new laboratory models, identifying how the immune system combats the infection, and uncovering molecular changes in the brain that could lead to future treatments. Unlike Lyme disease, Powassan virus has no specific treatment or vaccine, making this research crucial as warming temperatures expand tick habitats.

UTHealth Houston Researchers Utilize Database to Track Long COVID Diagnoses and Patterns

UTHealth Houston Researchers Utilize Database to Track Long COVID Diagnoses and Patterns

Researchers at UTHealth Houston have utilized the Texas All-Payer Claims Database (TX-APCD) to analyze patterns in long COVID diagnoses across various populations and SARS-CoV-2 variant periods from October 2021 to October 2023. This initiative aims to fill a significant gap in long COVID surveillance, as no comprehensive system comparable to those used for acute COVID-19 cases, hospitalizations, and deaths currently exists for the chronic condition. The study, published in the International Journal of Infectious Diseases, revealed that long COVID diagnoses generally followed waves of acute COVID-19 infection, with peaks in emergency department visits preceding increases in long COVID claims by two to three weeks. The database, established by the 87th Texas Legislature in 2021, covers nearly 60% of insured Texans and includes medical, pharmacy, and dental claims, along with eligibility and provider files from private and public payers. This allows for a detailed examination of how documented long COVID dif...

Alzheimer's Research Reveals Immune Response Outside Brain May Drive Neurodegeneration

Alzheimer's Research Reveals Immune Response Outside Brain May Drive Neurodegeneration

Recent scientific findings suggest that the danger of Alzheimer's disease may originate from outside the brain, challenging the traditional view of it solely as a brain ailment. A new study indicates that an immune response, specifically involving T cells, can attack the brain and cause neurodegeneration, a hallmark of Alzheimer's. Researchers previously identified T cells in abundance in the brains of mice with elevated levels of the 'tau' protein, one of the key proteins associated with Alzheimer's. Eliminating or inhibiting these T cells in mice led to reduced nerve cell damage. The latest research, conducted on mice, further reveals that a specific type of T cells, CD8+ T cells, can be directed to enter the brain through interactions with conventional dendritic cells type 1 (cDC1). These cDC1 cells act as immune system guardians, identifying targets and signaling CD8+ T cells. Experimentally eliminating cDC1 cells or disabling their ability to 'cross-present' in genetically modified mice with tau prote...

Regulatory Frameworks Lag Behind Adaptive Platform Trials in Drug Development

Regulatory Frameworks Lag Behind Adaptive Platform Trials in Drug Development

The field of infectious disease research has seen significant advancements with the implementation of adaptive platform trials, such as REMAP-CAP and RECOVERY, particularly during the COVID-19 pandemic. These trials, which can continuously evolve by adding or removing treatment arms based on accumulating evidence, have demonstrated the ability to generate robust efficacy signals at an unprecedented speed. For instance, REMAP-CAP enrolled nearly 5,000 critically ill COVID-19 patients across 25 countries, and its broader sub-study included over 9,000 participants, allowing for rapid evaluation of various interventions like immunoglobulin therapy and corticosteroid dosing. The RECOVERY trial, utilizing NHS infrastructure, similarly identified the effectiveness of casirivimab and imdevimab in reducing mortality for hospitalized COVID-19 patients. Despite the proven scientific and operational efficacy of these dynamic trial designs, current regulatory frameworks, including the FDA's 2023 draft guidance on Maste...

Study Suggests Routine Newborn Screening for Cytomegalovirus Could Detect More Cases

Study Suggests Routine Newborn Screening for Cytomegalovirus Could Detect More Cases

A three-year study conducted at Hadassah Medical Center in Jerusalem, led by Dana Wolf, Smadar Eventov Friedman, and Moran Yassour, indicates that routine newborn screening for congenital cytomegalovirus (cCMV) could significantly increase detection rates. The study, published in The Lancet Infectious Diseases, screened 48,556 newborns, identifying 176 infants with cCMV, which translates to approximately 3.6 cases per 1,000 babies. A key finding was that 57% of these cCMV cases (100 out of 176) would have gone undetected under the more common targeted screening approach, which typically tests babies only when there are suspicious signs like a failed hearing test or known maternal infection. Among these 100 babies who appeared healthy at birth, eight later developed moderate to severe cCMV signs, and three experienced hearing loss despite initially being asymptomatic. Eleven ultimately received antiviral treatment. The researchers utilized a pooled saliva-testing system, adapted from a COVID-19 PCR testing ...

University of Vermont Secures $19 Million NSF Grant to Establish National Microscope Hub for Brain Mapping

University of Vermont Secures $19 Million NSF Grant to Establish National Microscope Hub for Brain Mapping

The University of Vermont (UVM) has been awarded a five-year, $19 million federal grant from the National Science Foundation (NSF) to create the National Connectomics and Ultrastructure Volume Observatory (NCUVO). This initiative will transform a research building in Burlington, Vermont, into the central hub for a new national science observatory. The NCUVO aims to utilize advanced electron microscopy, artificial intelligence, and powerful computing networks to visualize cells and brain circuits in three dimensions, enabling scientists to study structures too small for traditional light microscopes. Of the total grant, $15.68 million is allocated to UVM, with the remaining $3.32 million going to the University of California San Diego. UVM President Marlene Tromp highlighted the transformative nature of this research, emphasizing the university's leadership role in this national endeavor. The project builds upon previous work by Davi Bock, a neuroscientist at UVM's Larner College of Medicine, whose lab prod...

The Columbus Dispatch

Tuberculosis care in Columbus evolved from an open-air camp to hospitals

Tuberculosis care in Columbus evolved from an open-air camp to hospitals

Before being released from the tuberculosis hospital in Columbus, patients had to have three negative tests which were done on live guinea pigs.

U.S. Officials Address Research Gaps in Menopause Care, Including Testosterone Use

U.S. Officials Address Research Gaps in Menopause Care, Including Testosterone Use

U.S. officials, including Dr. Dorothy Fink, deputy director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, are calling for more specific research into menopause care, particularly concerning the use of testosterone to treat symptoms. This comes as testosterone is increasingly promoted on social media as a 'cure-all' for menopause symptoms, despite a lack of solid scientific backing for its widespread use. The debate over testosterone is occurring against a backdrop of menopausal hormone therapy moving mainstream after years of declining use due to past methodological flaws in studies that skewed perceived risks. While the Journal of Obstetrics and Gynaecology issued a guideline in 2021 affirming menopausal hormone therapy as the 'most effective option' for symptoms like hot flashes for most women under 60 or less than 10 years post-menopause, the scientific community emphasizes the need for evidence-based approaches, especially for newer treatments like testosterone...

Ventura County Star, Camarillo

Medications for weight loss — a GLP-1 update | Dr. Loh

Medications for weight loss — a GLP-1 update | Dr. Loh

Given all the press and popularity of the GLP-1 receptor agonists, it may be good time for a review of where we are with this class of medications.

Vital Signs Research Group Conducts FDA-Compliant Glucometer Testing and Validation Studies in San Francisco

Vital Signs Research Group Conducts FDA-Compliant Glucometer Testing and Validation Studies in San Francisco

Vital Signs Research Group, located in San Francisco, CA, is actively conducting glucometer testing and validation studies to meet stringent FDA accuracy requirements for blood glucose monitoring devices. These studies are crucial for manufacturers seeking FDA 510(k) clearance for their products, which range from traditional fingerstick glucometers to continuous glucose monitoring (CGM) adjacent devices. The research group designs clinical studies tailored to the specific intended use, target population, and regulatory pathway of each device. Their testing protocols align with FDA guidance on blood glucose monitors and applicable ISO 15197 accuracy standards for non-significant risk devices. All studies are reviewed and approved by an external Institutional Review Board (IRB), Advarra, and adhere to ISO 14155, FDA 21 CFR 50, and FDA 21 CFR 812 regulations. The company recruits study participants from a pre-screened database, ensuring a diverse range of glucose levels and demographics to meet FDA requiremen...

Tirzepatide Activates Calorie-Burning Brown Fat, Offering New Insights for Obesity Treatment

Tirzepatide Activates Calorie-Burning Brown Fat, Offering New Insights for Obesity Treatment

A new study in mice suggests that tirzepatide, the active ingredient in drugs like Zepbound and Mounjaro, may improve metabolism by directly activating brown adipose tissue, a type of fat that specializes in burning calories. Tirzepatide is approved for weight management in adults with obesity or overweight with comorbidities, and for treating type 2 diabetes. Unlike other obesity medications, tirzepatide targets receptors for two hormonal factors, GIP and GLP-1, leading to substantial weight loss primarily by reducing food intake. Researchers, led by Marion Peyrou, investigated whether tirzepatide also produces metabolic changes beyond appetite suppression. By comparing obese mice treated with tirzepatide to those given the same amount of food without the drug, they found that tirzepatide activated brown fat, increasing its capacity to burn metabolic energy and produce beneficial molecules called batokines.

Research Explores Individual Differences in COVID-19 Vaccine Side Effects

Research Explores Individual Differences in COVID-19 Vaccine Side Effects

New research indicates that individual differences in innate immune responses may explain why some people experience more pronounced temporary side effects after COVID-19 vaccination, while others have minimal reactions. A study led by Professor Arnaud Didierlaurent at the University of Geneva monitored immune responses in 51 healthy individuals before and after receiving two doses of an mRNA COVID-19 vaccine. The findings suggest that people with a more active interferon-related immune signature prior to vaccination tend to have stronger reactions. Interferons are signaling molecules released by cells upon detecting viral infection, which prime neighboring cells for defense. The study also identified a potential reason for stronger reactions after a second vaccine dose: antibodies and T-cells generated by the first dose can amplify inflammation, leading to the recruitment and activation of innate immune cells at the injection site. These inflammatory molecules may then enter the bloodstream, contributing ...